<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03209414</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol ver. 1 08 May 2017</org_study_id>
    <nct_id>NCT03209414</nct_id>
  </id_info>
  <brief_title>Frailty Syndrome in Daily Practice of Interventional Cardiology Ward</brief_title>
  <acronym>FRAPICA</acronym>
  <official_title>Frailty Syndrome in Daily Practice of Interventional Cardiology Ward</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Silesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Silesia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The impact of frailty on immediate and long term outcomes of invasive treatment of coronary
      artery disease is not fully characterized. The assessment of frailty may help physicians in
      the selection of best treatment option and in the timing and modality of the follow-up. The
      FRAilty syndrome in daily Practice of Interventional CArdiology ward (FRAPICA) study is
      designed with the aim to validate the use of the Fried frailty scale and instrumental
      activities of daily living scale (IADL) as prognostic tools in patients admitted to hospital
      for symptomatic coronary artery disease, either stable, unstable, or acute coronary syndrome
      (ACS).

      The FRAPICA study is a single center prospective study enrolling patients aged ≥65 years. The
      aims are (1) to describe Fried frailty scale and IADL scale distribution before hospital
      discharge and (2) to investigate the prognostic role of Fried frailty and IADL scores. The
      outcomes are: (1) results of invasive treatment, (2) its complications (periinterventional
      MI, contrast-induced nephropathy, blood loss), (3) three-year all-cause mortality,
      cardiovascular mortality, stroke, myocardial infarction, reintervention, heart failure,
      hospital readmission for any cause, and a composite of the above mentioned. Ancillary
      analyses will be focused on different clinical presentations, different tools to assess
      frailty and risk stratification.

      The FRAPICA program will fill critical gaps in the understanding of the relation between
      frailty, cardiovascular disease, interventional procedures and outcome. It will enable more
      personalized risk assessment and identification of new targets for interventions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2017</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Predischarge distribution of frailty syndrome according to Fried phenotype frailty scale</measure>
    <time_frame>Up to hospital discharge, on average day 4</time_frame>
    <description>Patients will be assessed with Fried frailty scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Predischarge distribution of frailty syndrome according to instrumental activities of daily living scale</measure>
    <time_frame>Up to hospital discharge, on average day 4</time_frame>
    <description>Patients will be assessed with instrumental activities of daily living scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Results of interventional treatment</measure>
    <time_frame>Up to hospital discharge, on average day 4</time_frame>
    <description>Number of patients with successful revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of periprocedural infarction</measure>
    <time_frame>Up to hospital discharge, on average day 4</time_frame>
    <description>Number of patients with periprocedural infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of contrast induced nephropathy</measure>
    <time_frame>Up to hospital discharge, on average day 4</time_frame>
    <description>Number of patients with contrast induced nephropathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of bleeding</measure>
    <time_frame>Up to hospital discharge, on average day 4</time_frame>
    <description>Number of patients with bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major cardiovascular events</measure>
    <time_frame>36 months</time_frame>
    <description>Number of cardiovascular deaths in long term follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major cardiovascular events</measure>
    <time_frame>36 months</time_frame>
    <description>Number of all-cause deaths in long term follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major cardiovascular events</measure>
    <time_frame>36 months</time_frame>
    <description>Number of patients with reinfarction in long term follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major cardiovascular events</measure>
    <time_frame>36 months</time_frame>
    <description>Number of patients with target lesion revascularization in long term follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major cardiovascular events</measure>
    <time_frame>36 months</time_frame>
    <description>Number of patients with stroke in long term follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major cardiovascular events</measure>
    <time_frame>36 months</time_frame>
    <description>Number of patients with new onset heart failure in long term follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major cardiovascular events</measure>
    <time_frame>36 months</time_frame>
    <description>Number of patients rehospitalized for any cause in long term follow-up</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Frail Elderly Syndrome</condition>
  <condition>Coronary Heart Disease</condition>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Coronary Artery Bypass Grafting</condition>
  <condition>Percutaneous Transluminal Coronary Angioplasty</condition>
  <arm_group>
    <arm_group_label>Stable coronary artery disease</arm_group_label>
    <description>Patients with stable effort angina wil be enrolled. Based on coronary angiography, heart team will decide on medical, percutaneous angioplasty, or bypass grafting.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unstable coronary artery disease</arm_group_label>
    <description>Patients with unstable angina wil be enrolled. Based on coronary angiography, heart team will decide on medical, percutaneous angioplasty, or bypass grafting.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-ST elevation myocardial infarction</arm_group_label>
    <description>Patients with non-ST elevation myocardial infarction wil be enrolled. Based on coronary angiography, heart team will decide on medical, percutaneous angioplasty, or bypass grafting.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ST-elevation myocardial infarction</arm_group_label>
    <description>Patients with ST elevation myocardial infarction wil be enrolled. In majority of patients primary percutaneous coronary intervention will be performed. Based on coronary angiography, heart team will decide on further medical treatment, percutaneous angioplasty, or bypass grafting.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      4 ml of blood plasma is frozen at -80 degrees of Celsius. SST2 will be assayed after
      completion of recruitment.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The investigators assume to enroll consecutive 1000 patients with symptomatic coronary
        artery disease admitted to 2nd Dept. of Cardiology in Zabrze, Medical University of Silesia
        for coronary angiography or interventional treatment of the disease. Patients of both sexes
        aged ≥ 65 years are eligible. An information on study rationale, objectives, and
        methodology is presented to patients and written, informed consent is required to
        participate in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged ≥ 65

          -  symptomatic coronary artery disease A) stable B) unstable C) NSTEMI D) STEMI

          -  written, informed consent

        Exclusion Criteria:

          -  lack of consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrzej R Tomasik, M.D. Ph.D., FESC</last_name>
    <phone>0048323732372</phone>
    <email>tomasik@poczta.onet.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ewa Nowalany-Kozielska, Prof.</last_name>
    <phone>0048323732372</phone>
    <email>kl2karz@sum.edu.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>II Dept. of Cardiology in Zabrze Medical University of Silesia</name>
      <address>
        <city>Zabrze</city>
        <state>Upper Silesia</state>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beata Matyjaszczuk</last_name>
      <phone>0048323732372</phone>
      <email>kl2karz@sum.edu.pl</email>
    </contact>
    <contact_backup>
      <last_name>Lidia Stankiewicz</last_name>
      <phone>0048323732372</phone>
      <email>kl2karz@sum.edu.pl</email>
    </contact_backup>
    <investigator>
      <last_name>Andrzej R Tomasik, MD PhD FESC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ewa Wołoszyn-Horak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Salamon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jakub Standera</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Łukasz Bieda</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katarzyna Chojnacka</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aleksandra Brzosko</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ewa Nowalany-Kozielska, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2017</study_first_submitted>
  <study_first_submitted_qc>July 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2017</study_first_posted>
  <last_update_submitted>July 3, 2017</last_update_submitted>
  <last_update_submitted_qc>July 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Silesia</investigator_affiliation>
    <investigator_full_name>Andrzej Tomasik MD PhD FESC</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>Frailty syndrome</keyword>
  <keyword>Coronary heart disease</keyword>
  <keyword>Coronary revascularization</keyword>
  <keyword>Major adverse cardiovascular events</keyword>
  <keyword>Arterial stiffness</keyword>
  <keyword>Applanation tonometry</keyword>
  <keyword>Lean body mass</keyword>
  <keyword>ST2 biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

